Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Ardelyx, Inc.NASDAQ: ARDX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $89.66M rose 46.5% year over year, ahead of the +29.0% change in trailing-twelve-month gross profit. Sequentially, it fell 21.0% from the prior quarter. Over 3 fiscal years it compounded at +96.5% a year.

Context

  • Gross profit amounted to 89.5% of revenue in FY2025, up 4.7 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +46.5% holds above the trailing-twelve-month pace of +29.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$89.66M-21.0% QoQ
Last fiscal yearDec 2025
$364.72M+28.9% YoY
LTMMar 2026
$393.18M+29.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.5%——
1 year+28.9%——
3-year CAGR+96.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
364.72M USD
Year-over-year change
+28.9%
4-year CAGR
+151.6%

Gross Profit vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 gross profit of $393.18M is the highest of the 5 companies compared; the peer median is $103.18M.
  • Its year-over-year change of +29.0% is the 3rd highest of 4, against a peer median of +39.8%.
  • Gross profit amounts to 91.9% of revenue for ARDX, versus a peer median of 81.6%.
ARDX Competitors Peer median
Gross Profit for ARDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$393.18M +29.0%+96.5%91.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$256.89M +42.5%+39.6%81.6%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$187.95M +39.8%-10.0%80.9%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$18.41M -89.0%—92.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding ARDX) $103.18M+39.8%+14.8%81.6%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.1M52.16M124.46M333.62M407.32M
Cost of Revenue1M4.12M17.8M50.56M42.6M
Gross Profit9.1M48.04M106.66M283.06M364.72M
Gross Margin90.1%92.1%85.7%84.8%89.5%
Research & Development91.14M35.2M35.54M52.32M68.47M
Selling, General & Admin72.3M76.6M134.4M258.69M337.23M
Operating Expenses163.44M111.8M169.94M311.01M405.7M
Depreciation & Amortization2.81M1.14M1.29M2.06M3.06M
EBITDA(150.85M)(60.98M)(55.35M)(16.71M)(29.17M)
EBITDA Margin-1494.0%-116.9%-44.5%-5.0%-7.2%
Operating Income(154.35M)(63.76M)(63.28M)(27.95M)(40.98M)
Operating Margin-1528.6%-122.2%-50.8%-8.4%-10.1%
Interest Income00000
Interest Expense4.5M5.07M8.87M20.09M28.4M
Other Income / Expenses(3.82M)(3.44M)(2.24M)(10.92M)(19.65M)
Income Before Tax(158.16M)(67.2M)(65.52M)(38.87M)(60.63M)
Pre-Tax Margin-1566.4%-128.8%-52.6%-11.7%-14.9%
Income Tax Expense4K8K547K266K969K
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Net Margin-1566.5%-128.9%-53.1%-11.7%-15.1%
EPS (Basic)(1.52)(0.42)(0.30)(0.17)(0.26)
EPS (Diluted)(1.52)(0.42)(0.30)(0.17)(0.26)
Weighted Avg Shares104.21M158.69M219.33M235.23M241.03M
Weighted Avg Shares (Diluted)104.21M158.69M219.33M235.23M241.03M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.